Featured in BiotechDispatch: Channel Bio opens new state-of-the-art facility in Sydney

Channel Bio recently launched its new state-of-the-art facility at The Grounds of Alexandria in Sydney, Australia. The large three-storey space can host over 100 scientists working to solve some of the toughest challenges in drug discovery.

To celebrate the opening, the Channel Bio team, led by Adam Clarke and Jonathan Nambiar, hosted members and supporters of the NSW biotechnology and research community. They also welcomed the executive team from AbCellera, which is Channel Bio’s parent company, including CEO Carl Hansen and COO Véronique Lecault.

Read the full coverage on BiotechDispatch

Featured on Forbes: AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases

“A biotech company partnering with major pharmaceutical players like Lilly on Covid-19 drug development is raising $105 million in funding to ramp up. AbCellera announced on Wednesday that it raised that sum in a Series B funding round led by OrbiMed and DCVC Bio. The investment takes the company’s total funding to about $115 million in its eighth year of operation.”

Read full coverage on Forbes.

Featured on FierceBiotech: Lilly-partnered AbCellera gets COVID-19 boost from Canadian government

“AbCellera said it will get up to $175.6 million in support from the government of Canada under its so-called Innovation, Science and Economic Development Canada Strategic Innovation Fund. This cash boost will be used to ‘expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19” as well as to build out new tech and manufacturing infrastructure for antibody therapies “against future pandemic threats.'”

Read full coverage on FierceBiotech.